Targeted therapeutic progression of EGFR mutation in non-small cell lung cancer with brain metastasis

doi:10.3760/cma.j.cn371439-20240318-00121

Abstract

Abstract:

Patients with brain metastases from non-small cell lung cancer （NSCLC） generally have a poor prognosis. Tyrosine kinase inhibitors （TKIs） have significantly improved the prognosis of patients with sensitizing mutations in the epidermal growth factor receptor （EGFR） gene. Combining TKIs with other treatments such as radiotherapy， chemotherapy， and anti-angiogenic therapy can improve survival of patients with EGFR-mutant NSCLC brain metastases. However， more in-depth clinical studies are needed to determine the best combination strategies and to identify which patient groups will benefit the most from these approaches.

Key words: Carcinoma， non-small-cell lung, Neoplasm metastasis, Radiotherapy, Molecular targeted therapy, Drug therapy， combination

Luo Yijun, Yao Weirong, Wang Xiaoli. Targeted therapeutic progression of EGFR mutation in non-small cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2024, 51(11): 717-722.

References 34

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[2]	胡韡, 张宇. 170例晚肺腺癌患者EGFR突变检测状况相关分析[J]. 国际肿瘤学杂志, 2019, 46(1): 11-16. DOI: 10.3760/cma.j.issn.1673-422X.2019.01.003.
[3]	Peng W, Pu X, Jiang M, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report[J]. Lung Cancer, 2021, 152: 66-70. DOI: 10.1016/j.lungcan.2020.12.008. pmid: 33352385
[4]	Lu S, Dong X, Jian H, et al. Aeneas: a randomized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27): 3162-3171. DOI: 10.1200/JCO.21.02641.
[5]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2023[M]. 北京: 人民卫生出版社, 2023.
[6]	Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625-635. DOI: 10.1016/S1470-2045(19)30035-X. pmid: 30975627
[7]	Zhou Q, Xu CR, Cheng Y, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study[J]. Cancer Cell, 2021, 39(9): 1279-1291.e3. DOI: 10.1016/j.ccell.2021.07.005. pmid: 34388377
[8]	Jiang T, Zhang Y, Li X, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer, 2019, 121: 98-108. DOI: 10.1016/j.ejca.2019.08.021. pmid: 31569068
[9]	Ninomiya T, Nogami N, Kozuki T, et al. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404[J]. Jpn J Clin Oncol, 2021, 51(8): 1269-1276. DOI: 10.1093/jjco/hyab084. pmid: 34115855
[10]	Kuo CHS, Chiu TH, Tung PH, et al. Afatinib treatment alone or with bevacizumab in a real-world cohort of non-small cell lung cancer patients with epidermal growth factor receptor mutation[J]. Cancers(Basel), 2022, 14(2): 316. DOI: 10.3390/cancers14020 316.
[11]	Kenmotsu H, Wakuda K, Mori K, et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study[J]. J Thorac Oncol, 2022, 17(9): 1098-1108. DOI: 10.1016/j.jtho.2022.05.006.
[12]	Chen H, Xia T, Huuang G, et al. Aumolertinib plus anlotinib as 1st-line treatment for EGFR mutant non-small cell lung cancer: a phase Ⅱ trial (ALWAYS)[J]. J Thorac Oncol, 2023, 18(S11): S346-S346. DOI: 10.1016/J.JTHO.2023.09.605.
[13]	Chen L, Chen J, Li M, et al. Aumolertinib plus anlotinib in advanced NSCLC with brain metastasis: a single-arm, phase Ⅱ study[J]. J Thorac Oncol, 2023, 18(S11): S48-S49. DOI: 10.1016/J.JTHO.2023.09.032.
[14]	Lai-Kwon J, Tiu C, Pal A, et al. Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer—a drug development perspective[J]. Crit Rev Oncol Hematol, 2021, 159: 103225. DOI: 10.1016/j.critrevonc.2021.103225.
[15]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2019[M]. 北京: 人民卫生出版社, 2019.
[16]	Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123. DOI: 10.1200/JCO.19.01488. pmid: 31682542
[17]	Hou X, Li M, Wu G, et al. Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases[J]. JAMA Network Open, 2023, 6(2): e2255050. DOI: 10.1001/jamanetworkopen.2022.55050.
[18]	Planchard D, Jänne P, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21): 1935-1948. DOI: 10.1056/NEJMoa2306434.
[19]	Li Y, Pan Z, Zhao Y, et al. Aumolertinib plus chemotherapy as 1st line treatment in advanced lung cancer EGFR mutation and ctDNA cleared analysis[J]. J Thorac Oncol, 2022, 17(S9): S397. DOI: 10.1016/J.JTHO.2022.07.685.
[20]	Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset[J]. J Thorac Oncol, 2019, 14(1): 99-106. DOI: 10.1016/j.jtho.2018.09.004. pmid: 30240852
[21]	Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases[J]. Nat Rev Cancer, 2020, 20(1): 26-41. DOI: 10.1038/s41568-019-0205-x. pmid: 31601988
[22]	Tanaka H, Karita M, Ueda K, et al. Differences in radiosensitivity according to EGFR mutation status in non-small cell lung cancer: a clinical and in vitro study[J]. J Pers Med, 2023, 14(1): 25. DOI: 10.3390/jpm14010025.
[23]	张静静, 马胜林, 吴琼. 人肺腺癌辐射耐受细胞株的建立及其放射抵抗机制探讨[J]. 中国肺癌杂志, 2023, 26(2): 93-104. DOI: 10.3779/j.issn.1009-3419.2023.102.08.
[24]	Chen H, Wu A, Tao H, et al. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis[J]. Medicine (Baltimore), 2018, 97(44): e13014. DOI: 10.1097/md.0000000000013014.
[25]	Du XJ, Pan SM, Lai SZ, et al. Upfront cranial radiotherapy vs. EGFR tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer: a meta-analysis of 1 465 patients[J]. Front Oncol, 2018, 8: 603. DOI: 10.3389/fonc.2018.00603.
[26]	Magnuson WJ, Lester-coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis[J]. J Clin Oncol, 2017, 35(10): 1070-1077. DOI: 10.1200/jco.2016.69.7144. pmid: 28113019
[27]	He Z, Li MF, Lin JH, et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study[J]. Cancer Manag Res, 2019, 11: 2129-2138. DOI: 10.2147/CMAR.S184922.
[28]	Miyawaki E, Kenmotsu H, Mori K, et al. Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases[J]. Int J Radiat Oncol Biol Phys, 2019, 104(3): 604-613. DOI: 10.1016/j.ijrobp.2019.02.051.
[29]	Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir Med, 2022, 10(11): 1019-1028. DOI: 10.1016/s2213-2600(22)00168-0.
[30]	Zhou Y, Wang B, Qu J, et al. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: osimertinib vs. first-generation EGFR tyrosine kinase inhibitors[J]. Lung Cancer, 2020, 150: 178-185. DOI: 10.1016/j.lungcan.2020.10.018. pmid: 33186860
[31]	Zhao Y, Li S, Yang X, et al. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis[J]. Int J Cancer, 2022, 150(8): 1318-1328. DOI: 10.1002/ijc.33904.
[32]	Dohm AE, Tang J, Mills MN, et al. Upfront treatment with osimertinib vs. osimertinib and radiotherapy for patients with EGFR-positive non-small cell lung cancer brain metastases[J]. Int J Radiat Oncol Biol Phys, 2022, 112(2): e14. DOI: 10.1016/J.IJROBP.2021.10.186.
[33]	Yu F, Ni J, Zeng W, et al. Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor-mutant non-small cell lung cancer with brain metastases[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3): 804-815. DOI: 10.1016/j.ijrobp.2021.05.125.
[34]	Chen J, Wang B, Fan M. Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): an update of a phase Ⅱ, prospective study[J]. Int J Radiat Oncol Biol Phys, 2023, 117(2): e94. DOI: 10.1016/J.IJROBP.2023.06.855.